Acteurs : Acteur Marc-André BIGARD

0
home-6208811
Nom
Pr Marc-André BIGARD
Coordonnées
Pr Marc-André BIGARDCentre Hospitalier Universitaire de NancyService d’Hépato-gastroentérologie Hôpital de Brabois Allée du Morvan

54511 Vandoeuvre-Lès-Nancy Cedex

Tel : +33 3 83 15 33 54
e/m : [email protected]

Affiliation(s)
Equipe de recherche
Equipe L30 – Laurence CHONE •
Aires d’expertise
Clinique:Hépato-Gastro-Entérologie
Axes du CGE
1 : Indicateurs de santé et évaluation des pratiques en cancérologie
Collègues
Equipe L30

  • Idrissia ABDELMOUTTALEB
  • Hélène BARRAUD
  • Jean-Pierre BRONOWICKI
  • Laurence CHONE
  • Hervé HUDZIAK
  • Jérôme WATELET
Projets
Equipe L30

2007 – CIRCE (porteur : Patrick HILLON)
FACTEURS DE RISQUE ENVIRONNEMENTAUX, NUTRITIONNELS ET METABOLIQUES DE CARCINOME HEPATOCELLULAIRE CHEZ LES MALADES ATTEINTS DE CIRRHOSE.
Publications


pixel-7724052
Billioud V, Laharie D, Filippi J, Roblin X, Oussalah A, Chevaux JB, Hebuterne X, Bigard MA, Peyrin-Biroulet L. Adherence to adalimumab therapy in Crohn’s disease: A French multicenter experience. Inflamm Bowel Dis. 2010 Nov 8.

pixel-7724052
Pillot C, Chevaux JB, Bigard MA, Peyrin-Biroulet L. Infliximab 10 mg/kg every 3 weeks for Crohn’s disease. Am J Gastroenterol. 2010 Nov;105(11):2509-10.

pixel-7724052
Oussalah A, Laurent V, Bruot O, Gueant JL, Regent D, Bigard MA, Peyrin-Biroulet L. Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn’s disease. Aliment Pharmacol Ther. 2010 Nov;32(9):1135-44. doi:

pixel-7724052
Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, Filippi J, Flourie B, Hebuterne X, Bigard MA, Peyrin-Biroulet L. A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. Am J Gastroenterol. 2010 Aug 24.

pixel-7724052
Oussalah A, Laurent V, Bruot O, Bressenot A, Bigard MA, Regent D, Peyrin-Biroulet L. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut. 2010 Aug;59(8):1056-65. Epub 2010 Jun 4.

pixel-7724052
Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis. 2010 Jun;16(6):916-24.

pixel-7724052
Oussalah A, Chevaux JB, Fay R, Sandborn WJ, Bigard MA, Peyrin-Biroulet L. Predictors of infliximab failure after azathioprine withdrawal in Crohn’s disease treated with combination therapy. Am J Gastroenterol. 2010 May;105(5):1142-9. Epub 2010 Apr 13.

pixel-7724052
Bouguen G, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn’s disease: clinical features, epidemiology, and treatment. Inflamm Bowel Dis. 2010 Aug;16(8):1431-42. – Review

pixel-7724052
Bouguen G, Roblin X, Bourreille A, Feier L, Filippi J, Nancey S, Bretagne JF, Flourie B, Hebuterne X, Bigard MA, Siproudhis L, Peyrin-Biroulet L. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010 Jun;31(11):1178-85. Epub 2010 Mar 8.

pixel-7724052
Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hebuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, van Assche G, Rutgeerts P, Lemann M, Colombel JF. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther. 2010 Jan;31(1):92-101. Epub .

pixel-7724052
Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009 Dec;33(12):1082-93. Epub .

pixel-7724052
Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Phelip JM, Bigard MA, Peyrin-Biroulet L. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Aliment Pharmacol Ther. 2009 Oct 15;30(8):854-63.

pixel-7724052
Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn’s disease in patients treated with infliximab. Aliment Pharmacol Ther. 2009 Oct;30(7):749-56. Epub 2009 Jul 6.

pixel-7724052
Bigard MA, Siproudhis L. [Anorectal disease: past, present, future] Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):713-23. Epub 2009 Aug 13.

pixel-7724052pixel-7724052
Sanou R, Anxionnat R, Taillandier L, Bigard MA, Regent D, Bracard S. Turcot syndrome: a case report J Radiol. 2009 Jul-Aug;90(7-8 Pt 1):842-4.

pixel-7724052
Peyrin-Biroulet L, Oussalah A, Bigard MA. Crohn’s disease: the hot hypothesis. Med Hypotheses. 2009 Jul;73(1):94-6. Epub 2009 Mar 6.

pixel-7724052
Oussalah A, Bigard MA, Peyrin-Biroulet L. Certolizumab use in pregnancy. Gut. 2009 Apr;58(4):608. – Comment

pixel-7724052
Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther. 2009 Feb 15;29(4):416-23. Epub 2008 Nov 25.

pixel-7724052
Peyrin-Biroulet L, Oussalah A, Boucekkine T, Bigard MA. TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine. Gastroenterol Clin Biol. 2009 Jan;33(1 Pt 1):23-30. Epub 2008 Dec 31.

pixel-7724052
Laclotte C, Oussalah A, Rey P, Bensenane M, Pluvinage N, Chevaux JB, Trouilloud I, Serre AA, Boucekkine T, Bigard MA, Peyrin-Biroulet L. [Helminths and inflammatory bowel diseases] Gastroenterol Clin Biol. 2008 Dec;32(12):1064-74. Epub 2008 Jul 10.

pixel-7724052
Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, Boucekkine T, Roblin X, Bigard MA, Peyrin-Biroulet L. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther. 2008 Oct 15;28(8):966-72. Epub 2008 Jul 24.

pixel-7724052
Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, Oussalah A, Seddik M, Canva V, Cortot A, Sogni P, Gueant JL, Bigard MA, Roblin X, Bronowicki JP. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther. 2008 Oct 15;28(8):984-93. Epub 2008 Jul 24.

pixel-7724052
Peyrin-Biroulet L, Bigard MA, Malesci A, Danese S. Step-up and top-down approaches to the treatment of Crohn’s disease: early may already be too late. Gastroenterology. 2008 Oct;135(4):1420-2. Epub 2008 Sep 4. – Comment

pixel-7724052
Bronowicki JP, Abdelmouttalebl D, Peyrin-Biroulet L, Venard V, Khiri H, Chabi N, Amouzou EK, Barraud H, Halfon P, Sanni A, Bigard MA, Le Faou A, Gueant JL. Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa J Hepatol. 2008 Apr;48(4):532-9. Epub 2008 Jan 2.

pixel-7724052
Chen M, Peyrin-Biroulet L, Xia B, Gueant-Rodriguez RM, Bronowicki JP, Bigard MA, Gueant JL. Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China. BMC Med Genet. 2008 Aug 13;9:78.

pixel-7724052
Bigard MA. [Therapeutic innovations in gastroesophageal reflux] Presse Med. 2007 Dec;36(12 Pt 3):1907-12. Epub 2007 May 24. – Review

pixel-7724052
Peyrin-Biroulet L, Oliver A, Bigard MA. Gossypiboma successfully removed by upper-GI endoscopy. Gastrointest Endosc. 2007 Dec;66(6):1251-2. – Comment

pixel-7724052
Peyrin-Biroulet L, Rodriguez-Gueant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA, Gueant JL. Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine. Am J Gastroenterol. 2007 May;102(5):1108-15. Epub 2007 Mar 13. – Review

pixel-7724052pixel-7724052
Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study World J Gastroenterol. 2007 Apr 28;13(16):2328-32.

pixel-7724052
Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007 Mar 15;25(6):675-80.